We are live on
!
Find out more
ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
1 hedge funds and large institutions have $72 invested in Adaptimmune Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
Holders
1
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
No buyers this quarter
Top Sellers
| 1 | -$37.8K | |
| 2 | -$20.8K | |
| 3 | -$11.3K | |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$9.2K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$483 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
RhumbLine Advisers
Boston,
Massachusetts
| $72 |
|
|||
|
EF
2
Empirical Finance
Havertown,
Pennsylvania
| – |
|
|||
|
RG
3
Rathbones Group
Liverpool,
United Kingdom
| – |
|
|||
|
XT
4
XTX Topco
George Town,
Cayman Islands
| – |
|
|||
|
JAIC
5
Josh Arnold Investment Consultant
Edina,
Minnesota
| – |
|
|||
|
6
Simplex Trading
Chicago,
Illinois
| – |
|
|||
7
Barclays
London,
United Kingdom
| – |
|